Literature DB >> 19902197

Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes.

Luca Gallelli1, Manuela Colosimo, Grazia A Tolotta, Daniella Falcone, Laura Luberto, Lucia S Curto, Pierandrea Rende, Francesca Mazzei, Norma M Marigliano, Giovambattista De Sarro, Salvatore Cucchiara.   

Abstract

AIM: Our aim was to compare the efficacy and tolerability of loperamide and racecadotril in elderly patients with acute diarrhea. RESEARCH DESIGN AND METHODS: We performed a randomized, prospective, double-blind, and parallel group design implemented in geriatric nursing homes in Catanzaro, Italy, from February 2008 to March 2009. Patients of both sexes were randomly allocated to receive either one tablet of racecadotril 100 mg every 8 h or two tablets of loperamide 2.0 mg followed by one tablet after each unformed stool, up to four tablets in any 24-h period. Patients were treated until recovery, defined as the production of two consecutive normal stools or no stool production for a period of 12 h.
RESULTS: Normal stools were collected 36 +/- 4 h after the beginning of racecadotril and in 63 +/- 6 h from the beginning of loperamide administration (P < 0.01). The median time of abdominal pain in the intent-to-treat (ITT) population was 14 h for racecadotril and 28 h for loperamide. In the per-protocol (PP) population, the median time of abdominal pain was 14 h for racecadotril and 32 h for loperamide (P < 0.01). About the 50% of patients experienced at least one adverse event during the study: 12% in the racecadotril group and 60% in the loperamide group. The most frequently occurring adverse events were nausea and constipation. Genetic analysis did not report the presence of rapid or poor metabolizers. Pharmacoeconomic analysis performed at the end of our study documented an increase in costs in the loperamide group with respect to the racecadotril group (P < 0.01).
CONCLUSIONS: Racecadotril is more effective than loperamide-probably due to drug interaction with loperamide-and it is not related to pharmacogenetic susceptibility. Racecadotril is also more cost effective than loperamide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19902197     DOI: 10.1007/s00228-009-0751-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  52 in total

Review 1.  Pharmacotherapeutics in older adults.

Authors:  Kathleen F Hunter; Daniel Cyr
Journal:  J Wound Ostomy Continence Nurs       Date:  2006 Nov-Dec       Impact factor: 1.741

2.  Racecadotril versus placebo in the treatment of acute diarrhoea in adults.

Authors:  H Hamza; H Ben Khalifa; P Baumer; H Berard; J M Lecomte
Journal:  Aliment Pharmacol Ther       Date:  1999-12       Impact factor: 8.171

Review 3.  Infectious diarrhea in the elderly.

Authors:  P K Slotwiner-Nie; L J Brandt
Journal:  Gastroenterol Clin North Am       Date:  2001-09       Impact factor: 3.806

4.  Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.

Authors:  J E Shook; P K Lemcke; C A Gehrig; V J Hruby; T F Burks
Journal:  J Pharmacol Exp Ther       Date:  1989-04       Impact factor: 4.030

Review 5.  Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis.

Authors:  Mark S Riddle; Sarah Arnold; David R Tribble
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

Review 6.  Diarrheal diseases in the elderly.

Authors:  Chantri Trinh; Kavita Prabhakar
Journal:  Clin Geriatr Med       Date:  2007-11       Impact factor: 3.076

7.  General outbreaks of infectious intestinal disease in England and Wales: 1995 and 1996.

Authors:  H S Evans; P Madden; C Douglas; G K Adak; S J O'Brien; T Djuretic; P G Wall; R Stanwell-Smith
Journal:  Commun Dis Public Health       Date:  1998-09

8.  Transmission of a small round structured virus by vomiting during a hospital outbreak of gastroenteritis.

Authors:  P R Chadwick; R McCann
Journal:  J Hosp Infect       Date:  1994-04       Impact factor: 3.926

9.  Role of CYP3A5 in abnormal clearance of methadone.

Authors:  Salvatore De Fazio; Luca Gallelli; Antonella De Siena; Giovambattista De Sarro; Maria Gabriella Scordo
Journal:  Ann Pharmacother       Date:  2008-05-06       Impact factor: 3.154

Review 10.  Acute diarrhea: a practical review.

Authors:  J Aranda-Michel; R A Giannella
Journal:  Am J Med       Date:  1999-06       Impact factor: 4.965

View more
  19 in total

1.  Remarks and questions on the article "Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes".

Authors:  Robert Hofmann
Journal:  Eur J Clin Pharmacol       Date:  2010-06-05       Impact factor: 2.953

2.  Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure.

Authors:  Antonio Siniscalchi; Francesco Scaglione; Enzo Sanzaro; Francesco Iemolo; Giorgio Albertini; Gianluca Quirino; Maria Teresa Manes; Santo Gratteri; Nicola Biagio Mercuri; Giovambattista De Sarro; Luca Gallelli
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

3.  Effects of Racecadotril on Weight Loss and Diarrhea Due to Human Rotavirus in Neonatal Gnotobiotic Pigs (Sus scrofa domesticus).

Authors:  Tammy Bui; Guohua Li; Inyoung Kim; Ke Wen; Erica L Twitchell; Shaoh Hualei; Ashwin K Ramesh; Mariah D Weiss; Xingdong Yang; Sherrie G Glark-Deener; Robert Km Choy; Lijuan Yuan
Journal:  Comp Med       Date:  2017-03-01       Impact factor: 0.982

Review 4.  Advances in the treatment of travelers' diarrhea.

Authors:  Mercedes Paredes-Paredes; Jose Flores-Figueroa; Herbert L Dupont
Journal:  Curr Gastroenterol Rep       Date:  2011-10

5.  Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy.

Authors:  Davide Zanon; Luca Gallelli; Francesca Rovere; Rossella Paparazzo; Natalia Maximova; Marzia Lazzerini; Antonio Reale; Tiziana Corsetti; Salvatore Renna; Tullia Emanueli; Francesco Mannelli; Francesco Manteghetti; Liviana Da Dalt; Caterina Palleria; Nicola Banchieri; Antonio Urbino; Mario Miglietta; Giovanni Cardoni; Adriana Pompilio; Alberto Arrighini; Clara Lazzari; Gianni Messi
Journal:  Eur J Pediatr       Date:  2012-12-04       Impact factor: 3.183

6.  2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.

Authors:  Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

7.  Characteristics and clinical implications of the pharmacokinetic profile of ibuprofen in patients with knee osteoarthritis.

Authors:  L Gallelli; O Galasso; A Urzino; S Saccà; D Falcone; C Palleria; P Longo; A Corigliano; R Terracciano; R Savino; G Gasparini; G De Sarro; S R Southworth
Journal:  Clin Drug Investig       Date:  2012-12       Impact factor: 2.859

8.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

9.  Safety and efficacy of generic drugs with respect to brand formulation.

Authors:  Luca Gallelli; Caterina Palleria; Antonio De Vuono; Laura Mumoli; Piero Vasapollo; Brunella Piro; Emilio Russo
Journal:  J Pharmacol Pharmacother       Date:  2013-12

Review 10.  Pharmacokinetic drug-drug interaction and their implication in clinical management.

Authors:  Caterina Palleria; Antonello Di Paolo; Chiara Giofrè; Chiara Caglioti; Giacomo Leuzzi; Antonio Siniscalchi; Giovambattista De Sarro; Luca Gallelli
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.